Pathologic evaluation of uterine leiomyoma treated
with radiofrequency ablation
Xin Luoa,⁎, Yuan Shena, Wen-Xia Songb, Pei-wen Chenb,
Xing-mei Xiea, Xiao-yu Wanga
aDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, China
bDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, China
Received 1 September 2006; received in revised form 26 March 2007; accepted 29 March 2007
Objective: To explore the mechanism by which radiofrequency ablation (RFA) treats uterine
leiomyoma by observing the features of the lesions caused by RFA to leiomyoma tissue. Methods:
Specimens from treated lesions were observed after hysterectomy was performed immediately
(acute test) or on the third day (chronic test) following treatment in 2 groups of 30 patients.
Histopathologic studies were also performed for all specimens, with untreated specimens as
controls.Results: For the acute and chronic tests, specimens from the RFA-treatedlesionsincluded
the center segment (group 1); the marginal segment (group 2); the segment 1-cm away from the
margin (group3); and the segment 2-cm away from the margin (group 4). In the acute test, group 1
showed a sharply demarcated area of coagulative necrosis that did not express estrogen receptor
2 and 3 than in the control group (Pb0.05), but ER and PRexpression in group 4, which had normal
carbonization and coagulation necrosis without ERor PRexpression. There was severe hemorrhage
and thrombosis in group 2; hyaline degeneration and tissue granulation in group 3; and mild
degeneration in group 4. The expression of ER and PR was significantly lower in groups 2, 3, and 4
than in the control group (Pb0.05). Conclusion: Radiofrequency ablation might treat uterine
leiomyomas by inducing coagulative necrosis and depressing ER and PR expression.
© 2007 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
All rights reserved.
Radiofrequency ablation (RFA)hasbeenusedtotreata variety
of neoplasms, including hepatocellular carcinoma, renal cell
carcinoma, hyper-functioning parathyroid adenoma, and
E-mail address: firstname.lastname@example.org (X. Luo).
0020-7292/$ - see front matter © 2007 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
All rights reserved.
available at www.sciencedirect.com
International Journal of Gynecology and Obstetrics (2007) 99, 9–13